FICHIT

Je m'inscris

ERYTECH PHARMA

0/5 (0 note(s))
Note donnée : aucune
Paris
159
A clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS technology, encapsulating therapeutic molecules in red blood cells.
ERYTECH’s lead product candidate ERY-ASP, also known under the trade name GRASPA®, has completed Phase 2/3 pivotal clinical trial in Europe with positive results, and a European Marketing Authorization Application was filed in September. ERYTECH also has an ongoing Phase 1 clinical trial of ERY-ASP in the United States in adults with newly diagnosed ALL, a Phase 2 clinical trial in Europe in elderly patients with AML, and a Phase 2 clinical trial in Europe in patients with metastatic pancreatic cancer. In addition to its current product candidates that focus on using encapsulated enzymes to induce tumor starvation, ERYTECH is exploring the use of its platform for developing cancer vaccines and enzyme replacement therapies.
BEYEN Gil
erytech.com
ERYP:FP

Fiche créée le 10/04/2016 par Guillaume   vue 13 fois.